Regenerative Medicine - Cardiac Regenerative Therapy and Rehabilitation

Cardiac Regenerative Therapy and Rehabilitation

Cardiovascular disease is a global problem of the century, with data showing that 1 in 4 deaths The disease, according to the global burden of disease first. In China, about 2.6 million people die of cardiovascular disease every year, with an average of 1 death every 13 seconds. Data from the "China Cardiovascular Health and Disease Report 2020" shows that the number of patients with cardiovascular disease has reached 3.3 Among them, 11.39 million coronary heart disease has become a major disease that threatens the health of the Chinese people.

Heart shock wave therapy and stem cell therapy are both based on this exploration, and they have also achieved considerable achievements in basic research and clinical experiments. With the country's strong support for precision medicine, stem cell clinical research, etc., Hans Heart Center has innovatively carried out D-SPEC precision rehabilitation with first-class precision rehabilitation concepts and top cardiac rehabilitation equipment. Assessing and improving myocardial ischemia with extracorporeal shock waves, and the precise cardiac health of a novel somatic cell technology with multi-target complex directional repair of autologous cells and tissue structure of monocyte-derived multi-effects cells (MDMC) Rehabilitation techniques.

1. D-SPECT is an accurate, efficient and safe screening and diagnosis of coronary heart disease

①Functional imaging is the gold standard for the diagnosis of myocardial ischemia and infarction in coronary heart disease 

②Accurate assessment of coronary stenosis and myocardial ischemia at two levels

③Myocardial ischemic coronary heart disease in general population

Screening probability and throughput for early diagnosis Compared with traditional SPECT, D-SPECT (specialized equipment for radionuclide myocardial perfusion imaging) increases the sensitivity by 10 times, the resolution by 2 times, the scanning speed by 10 times, and the radiation dose is reduced from 14mSv to 3mSv, heart gated collection can be completed in only two minutes, which greatly improves the efficiency and flow of clinical examination. This technology truly realizes the intelligent, safe, efficient and precise development goals of cardiac nuclear medicine. It has the advantages of simplicity, non-invasiveness, safety and high diagnostic accuracy.

2, A Novel Revascularization Therapy——Extracorporeal Cardiac Shock Wave Therapy (CSWT)

In clinical practice, patients with severe coronary heart disease have experienced coronary artery bypass grafting, percutaneous coronary intervention , β-blockers, thrombolytic drugs, antiplatelet drugs, statins, angiotensin-converting enzyme inhibitors/angiotensin II receptor antagonist drugs, lifestyle interventions, etc., but the therapeutic effect of coronary heart disease No significant improvement has been seen, and many patients still face threats such as recurrent angina pectoris attacks, decreased exercise tolerance, heart failure, and sudden death.  

Extracorporeal cardiac shock wave therapy (CSWT) combined with stem cell transplantation for angiogenesis can promote endogenous and exogenous Proliferation, homing to ischemic tissue, migration and differentiation of sex stem cells, improving the colonization rate and survival rate of stem cells by "improving soil", inducing the establishment of collateral circulation, and realizing "ultrasound bypass" "; induces angiogenesis in ischemic myocardium, increases capillary density in myocardium, rescues damaged cardiomyocytes, and improves cardiac function and symptoms related to myocardial ischemia in patients. Especially in patients with advanced refractory angina pectoris and ischemic heart failure, it brings significant improvement. Revascularization therapy does not require anesthesia, cardiac intervention and thoracotomy, and is non-invasive, painless and safe.

Extracorporeal cardiac shock wave is a non-invasive, safe and effective new vascular regeneration therapy, which can relieve angina pectoris for a long time . The CSWT system has successively started clinical application research in 9 countries including Germany, Japan, Switzerland, Italy, and China, and achieved good curative effect and research results.  

Extracorporeal cardiac shock wave therapy (CSWT) is a safe and effective treatment for severe coronary heart disease. It can improve the symptoms of myocardial ischemia in patients with severe coronary heart disease, and the patients have responded well after treatment. At the same time, cardiac shock wave therapy can promote angiogenesis, induce stem cell proliferation and differentiation, anti-inflammatory, antioxidant and other effects.

Heart regeneration treatment is suitable for:

①The patient has angina pectoris and myocardial ischemia, but refuses to accept or is not suitable for coronary catheterization or coronary artery bypass surgery.

②Existing drug treatment or stent placement or coronary artery After bypass surgery, but still have angina symptoms.  

③Patients who have undergone multiple coronary interventions, but the response is not good .

④Diffuse vascular disease with severe coronary stenosis, expected to receive coronary catheter Treatment or coronary bypass surgery is ineffective, which is often seen in patients with chronic renal failure/dialysis or poorly controlled diabetes.